Foghorn Therapeutics Inc. (FHTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript
Foghorn Therapeutics Inc. ( FHTX ) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs October 30, 2025 12:00 PM EDT Company Participants Karin Hellsvik - Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations Adrian H. Gottschalk - President, CEO & Director Steven Bellon - Chief Scientific Officer Alfonso Quintas-Cardama - Chief Medical Officer Conference Call Participants Gavin Clark-Gartner Steven Ionov Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Yuan Zhi - B.
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago.
